Research programme: serotonin 2A receptor agonists - Bright Minds Biosciences
Alternative Names: 5-HT2A receptor agonists - Bright Minds BiosciencesLatest Information Update: 28 Mar 2025
At a glance
- Originator Bright Minds Biosciences
- Class Antidepressants; Anxiolytics
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Major depressive disorder in Canada
- 28 Mar 2025 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in Canada
- 22 Sep 2021 Bright Minds Biosciences plans a clinical trials for Major depressive disorder and Post-traumatic stress disorders in the second half of 2022